Last updated on August 2018

Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Lower Risk MDS

Brief description of study

The objective of this study to evaluate the efficacy and safety of FG-4592 for the treatment of anemia in Chinese subjects with lower risk MDS.

Detailed Study Description

This is a Phase 2/3 trial with sequential Phase 2 and Phase 3 components. In each, there is an up to 4 weeks screen period followed by a treatment period of 26 weeks and a 4 week follow up period.

Clinical Study Identifier: NCT03303066

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.